Company: PRME
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023486
Chunk: 26

Company: Prime Medicine, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 26
---
 EndedMarch 31,(in thousands, except share and per share amounts)20252024Revenue:Collaboration revenue — related party$1,454 $— Collaboration revenue— 591 Total revenue1,454 591 Operating expenses:Research and development40,562 37,774 General and administrative13,284 11,158 Total operating expenses53,846 48,932 Loss from operations(52,392)(48,341)Other income:Interest income1,182 676 Accretion (amortization) of investments339 830 Change in fair value of short-term investment — related party(1,056)1,166 Other income, net37 42 Total other income, net502 2,714 Net loss before income taxes(51,890)(45,627)Provision for income taxes— (134)Net loss attributable to common stockholders$(51,890)$(45,761)Net loss per share attributable to common stockholders, basic and diluted$(0.40)$(0.44)Weighted-average common shares outstanding, basic and diluted130,884,490 104,466,178 Comprehensive loss:Net loss$(51,890)$(45,761)Change in unrealized loss on investments, net of tax(16)(80)Comprehensive loss$(51,906)$(45,841)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

6

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

Common StockAdditionalPaid-inCapitalAccumulated OtherComprehensiveLossesAccumulatedDeficitTotalStockholders’Equity(in thousands, except share amounts)SharesAmountBalance as of December 31, 2024131,160,842 $2 $840,358 $1 $(687,212)$153,149 Stock-based compensation expense— — 5,681 — — 5,681 Change in unrealized loss on investments, net of tax— — — (16)— (16)Net loss— — — — (51,890)(51,890)Balance as of March 31, 2025131,160,842 $2 $846,039 $(15)$(739,102)$106,924